Document is current

Article History

Received: 16 June 2024

Accepted: 6 October 2024

First Online: 21 October 2024

Declarations

:

: The authors report the following competing interests, all outside the submitted work. VS: Received research grants to institution from Abbvie, Biocept, Pfizer, Novartis, Puma Biotechnology, and QUE Oncology; In kind clinical trial assays from Foundation Medicine; Advisory board: Novartis. Chair, Data Safety Monitoring Board, AstraZeneca, all outside the submitted work. AO: None. BPS: Research support (drug only) from Genentech and Pfizer. Research support (testing support only) from Foundation Medicine and Epic Sciences, all outside the submitted work. TCS: None. MCL: Received research grants to institution from Eisai, Exact Sciences, Genentech, Genomic Health, GRAIL, Menarini Silicon Biosystems, Merck, Novartis, Seattle Genetics, Tesaro; Honoraria from Astra Zeneca, Celgene, Roche/Genentech, Genomic Health, GRAIL, Ionis, Merck, Pfizer, Seattle Genetics, Syndax to institution. Travel support from AstraZeneca, Genomic Health, Ionis; Employment and stock options Natera Inc., all outside the submitted work. CL: In kind clinical trial research support from Veracyte (formerly Nanostring). Advisory board: Novartis. Data safety monitoring board: SBI ALApharma, all outside the submitted work. MPG: MPG is the Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D. and reports personal fees for CME activities from Research to Practice, Clinical Education Alliance, Medscape, and MJH Life Sciences; personal fees serving as a panelist for a panel discussion from Total Health Conferencing and personal fees for serving as a moderator for Curio Science; consulting fees to Mayo Clinic from ARC Therapeutics, AstraZeneca, Biotheranostics, Blueprint Medicines, Lilly, Rna Diagnostics, Sanofi Genzyme, Seattle Genetics and Engage Health Media; and grant funding to Mayo Clinic from Lilly, Pfizer, Sermonix, Loxo, AstraZeneca and ATOSSA Therapeutics. He is an inventor on a patent application entitled “Degrading PKCb1 to Treat Cancer.” CSV: None. JAS: None. DV: Honoraria and advisory boards from Janssen, AstraZeneca, BeiGene, Abbvie, Roche, Kite/Gilead, BMS/Celgene, Zetagen, Merck, Incyte. Research funding (to the institution): Roche, AstraZeneca, all outside the submitted work. PS: None. PSC: None. DFM: None. GWS: Employment Caris Life Sciences, all outside the submitted work. The authors declare no competing interests.

: E3108 received approval from each of the participating sites.

: A written informed consent was obtained from all individuals included in E3108 for participation and publication.